Rosiglitazone sodium is a synthetic antidiabetic medication primarily used in the management of type 2 diabetes mellitus. It belongs to the thiazolidinedione class of drugs, which function as agonists of the peroxisome proliferator-activated receptor gamma (PPAR-γ). This action enhances insulin sensitivity in peripheral tissues, thereby improving glucose uptake and utilization. Rosiglitazone is characterized by its sodium salt form, which enhances its solubility and bioavailability. The compound typically appears as a white to off-white powder and is soluble in water and methanol. Its molecular formula includes carbon, hydrogen, nitrogen, oxygen, and sodium, reflecting its complex structure. While effective in controlling blood sugar levels, rosiglitazone has been associated with potential cardiovascular risks, leading to its restricted use in some regions. The drug is usually administered orally and may be prescribed alone or in combination with other antidiabetic agents. As with any medication, monitoring for side effects and efficacy is essential during treatment.

Rosiglitazone sodium

316371-83-2: Rosiglitazone sodium is a synthetic antidiabetic medication primarily used in the management of type 2 diabetes mellitus. It belongs to the thiazolidinedione class of drugs, which function as agonists of the peroxisome proliferator-activated receptor gamma (PPAR-γ). This action enhances insulin sensitivity in peripheral tissues, thereby improving glucose uptake and utilization. Rosiglitazone is characterized by its sodium salt form, which enhances its solubility and bioavailability. The compound typically appears as a white to off-white powder and is soluble in water and methanol. Its molecular formula includes carbon, hydrogen, nitrogen, oxygen, and sodium, reflecting its complex structure. While effective in controlling blood sugar levels, rosiglitazone has been associated with potential cardiovascular risks, leading to its restricted use in some regions. The drug is usually administered orally and may be prescribed alone or in combination with other antidiabetic agents. As with any medication, monitoring for side effects and efficacy is essential during treatment.

Rosiglitazone sodium is an effective and selective PPARγ activator, with EC50 values of 30 nM for PPARγ1, 100 nM for PPARγ2, and 60 nM for PPARγ. It also has an approximate Kd of 40 nM for PPARγ. Additionally, Rosiglitazone sodium acts as a regulator of TRP channels, inhibiting the activities of TRPM2 and TRPM3, while activating TRPC5.

CAS 316371-83-2

Rosiglitazone sodium

Rosiglitazone sodium

Ref: IN-DA00I5ZZ

Rosiglitazone sodium

Ref: TM-T200945